News

Scientists at the Louisiana State University Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells.

While the surgeons reported that the BW filter provided higher contrast during nucleus and viscous removal and posterior capsular polishing, they subjectively reported no significant advantage of using a BW filter.

No effect when used with orthokeratology lenses for 2 years.

Treatment and reduces burden of care, providing a treatment option for patients diagnosed with diabetic macular edema.

MyMD Pharmaceuticals Inc. announced recently that it has entered into a material transfer agreement with Bascom Palmer Eye Institute of Miami, Florida to collaborate on a pre-clinical study using MYMD-1 as a potential treatment for traumatic optic neuropathy.

According to the company, the study assesses the safety and tolerability of a single dose of CLS-AX administered to patients diagnosed with wet AMD by suprachoroidal injection.

Trial is evaluating the use of the Technolas TENEO excimer laser for vision correction surgery for hyperopia with astigmatism.

According to the company, new imaging options presenting opportunity for better outcomes for patients.

Results from the U.S. pivotal trial showed Apthera IOL subjects achieved statistically superior uncorrected intermediate and near vision, and equivalent distance vision and contrast sensitivity compared to control subjects.

Mount Sinai study could lead to earlier and increased screening for this population to prevent blindness.

A novel computational platform developed by researchers from the University of Pittsburgh School of Medicine identifies top-performing viral vectors that could deliver gene therapies to the retina with maximum efficiency and precision.

According to the Nanoscope Therapeutics, 6-month safety and efficacy data are expected in Q1 2023. MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive.

According to the company, 6-month safety and efficacy data are expected in Q1 2023. MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive.

The effects of cataract surgery are generally evaluated based on improvements in vision, but investigators sought to identify if the structures in the back of the eye were affected as well.

The companies will jointly develop 4D bio-fabricated corneal transplants for diseases that require endothelial keratoplasty and natural lenticule transplants.

A national poll suggests most parents overlook simple steps to protect children’s eyes; 1 in 7 parents say their child has not had a vision test in 2 years.

The findings could lead to a new understanding of unexplained causes of heritable retinal diseases.

The threshold limit value is increased for virus and bacterial eradication.

Pediatric ophthalmologists may need background information when treating young patients.

Eyes of mice lacking protective protein show signs similar to age-related macular degeneration.

LBS-008 is the company’s orally administered tablet for the treatment of Stargardt disease. There are currently no FDA approved treatments for Stargardt disease or dry AMD.

NIH-funded clinical trial finds that starting with a cheaper drug and switching to a more expensive drug as needed leads to good vision outcomes in diabetic macular edema.

Janet B. Serle, MD, discusses the pros and cons of various treatment options.

A novel eye drop under development may provide neuroprotection to the retinal ganglion cells.

Physicians use a new administration method to treat patients diagnosed with noninfectious uveitis.

According to a team of investigators from Yale, Stanford and Dartmouth, the variances in regional healthcare spending are not limited to either public or private payers.